Volume 2, Suppl. 1 (LATINFARMA 2013)

J Pharm Pharmacogn Res 2(Suppl. 1), (May) 2014

banner_g_4

Special supplement with the abstract book of LATINFARMA 2013

Abstracts of LATINFARMA HABANA 2013 (20mo Congreso Latinoamericano de Farmacología y Terapéutica, 5to Congreso Iberoamericano de Farmacología, 5to Congreso Internacional y 11no Congreso Nacional, de la Sociedad Cubana de Farmacología. Palacio de las Convenciones de La Habana, Cuba, October 21 – 25, 2013.

 

Plenary Lectures
Conferences
Oral Communications
Posters
Download the Full-Text Free Book in PDF:
Presentationjppres_pdf_free[697 Kb] / Abstractsjppres_pdf_free [4.44 Mb]
Plenary Lectures
PL 001: BIOLOGICAL AND THERAPEUTIC RELEVANCE OF THE DISCOVERY OF PROSTACYCLIN AND NITRIC OXIDE: Moncada S. [HTML]
PL 002: IMMUNOTHERAPY AND COMPLEXITY: OVERCOMING THE BARRIERS FOR THE CONTROL OF ADVANCED CANCER: Lage Dávila A.[HTML]
PL 003: TRENDS OF RESEARCH IN THE 21RST CENTURY: Moncada S. [HTML]
PL 005: PERSONALIZED CANCER VACCINES: WHO SHOULD PICK THE TARGET?: Overwijk WW. [HTML]
PL 006: DRUG METABOLISM IN THE BRAIN AND HOW IT CAN ALTER DRUG RESPONSE: Tyndale R. [HTML]
PL 007: SEPSIS, INFLAMMATION AND CELL RESPONSE: Salomao R. [HTML]
PL 008: OLD REMEDIES FOR NEW AILMENTS – PRESENT TIME OF THE PHYTOMEDICINES: Alonso J. [HTML]
PL 009: CEIBA: PHARMACOGENETICS IN IBEROAMERICANS AND ITS CLINICAL IMPLICATIONS: Llerena A. [HTML]
PL 010: PHARMACOLOGICAL MANAGEMENT OF NEUROPATHIC PAIN: Granizo E. [HTML]
PL 014: CAUSES OF DISEASES AND THEIR BOARDING FROM THE PERSPECTIVE OF ORTHOMOLECULAR MEDICINE: Llorente JR. [HTML]
Top page
Conferences
C 003: INTERNATIONAL VALIDATION AND REGULATORY ACCEPTANCE OF ALTERNATIVE METHODS: PROGRESSES AND PROSPECTS: Eskes C. [HTML]
C 004: THE DISCREET FASCINATION OF THE DRUGS: Pérez J. [HTML]
C 005: PHARMACOKINETIC CHANGES INDUCED BY SPINAL CORD INJURY: Castañeda G. [HTML]
C 006: BETWEEN HYPERTENSION AND PAIN: Henrique Ferreira S. [HTML]
C 007: PHENOTYPIC MODIFICATIONS OF PRIMARY AFFERENT NEURONS INNERVATING OSTEOARTHRITIC JOINTS: Castro-Lopes JM et al. [HTML]
C 008: THE RATIONALE OF ANALGESIS COMBINATIONS: Granizo E. [HTML]
C 009: CARDIOVASCULAR RISK OF NONSTEROIDAL ANTI-INFLAMMATORY DRUG FREQUENTLY USED: Prozzi GR. [HTML]
C 010: FLAVANOLS MODULATE THE TRANSCRIPTION OF GENES INVOLVED IN ATHEROSCLEROSIS WITH HETEROGENIC EPIGENETIC CHANGES OF THEIR DNA METHYLATION STATE: Weseler AR et al. [HTML]
C 011: EPIGENETIC DEREGULATION IN CANCER: THERAPEUTIC APPLICATIONS: Berdasco M. [HTML]
C 012: EPIGENETIC REGULATION OF BREAST CANCER METASTASIS BY STEROIDAL LACTONE WITHAFERIN A: Szarcvel Szic K et al. [HTML]
C 013: PROMISES & CHALLENGES OF MICRORNAS IN MULTIPLE MYELOMA THERAPY: Palagani A et al. [HTML]
C 015: EFFECT OF DNA DEMETHYLATION ON CYP1A1 GENE EXPRESSION IN RAT CELLS: Olguín-Reyes S et al. [HTML]
C 017: LOW LEVEL LASER THERAPY (LLLT): THERAPEUTIC EFFECTS, DOSES, INDICATIONS AND CONTRAINDICATIONS, SIDE EFFECTS: Fornaini et al. [HTML]
C 019: OZONE´S THERAPEUTICAL TARGETS. BASIS OF THEIR PLEIOTROPIC EFFECTS: León Fernández OS et al. [HTML]
C 020: OZONE CONDITIONING EFFECT, NRF2 PATHWAY AND EPRE. AN IN VIVO STUDY DURING MAYOR AUTHO-HEMOTHERAPY: Re L et al. [HTML]
C 021: CRITERIA FOR THE REGULATION OF THE PRICE OF MEDICINES: Rovira J. [HTML]
C 022: THE GUANINE-BASED PURINERGIC SYSTEM AS A NEW TARGET FOR NEUROPROTECTION AGAINST GLUTAMATERGIC EXCYTOTOXICITY: Souza DO. [HTML]
C 023: PRECLINICAL STUDIES OF A NEW HYBRID MOLECULE WITH NEUROPROTECTIVE EFFECTS IN THE TREATMENT OF CEREBRAL ISCHEMIA: Nuñez Y et al. [HTML]
C 024: Achyrocline satureioides (LAM) D.C. (MARCELA): PROTECTIVE EFFECTS IN PRIMARY NEURONAL CULTURES AND AGAINST AN ISCHEMIC INJURY IN VIVO: Rivera F et al. [HTML]
C 025: GENETIC VARIATION IN SMOKING AND LUNG CANCER: Tyndale R. [HTML]
C 026: PHARMACOGENETICS: CLINICAL IMPLICATIONS FOR EATING DISORDERS AND SUICIDE: Llerena A et al. [HTML]
C 027: ANCIENT DNA STUDIES BRING NEW LIGHT ON THE EPIDEMIOLOGY OF TUBERCULOSIS: Bercovier H. [HTML]
C 028: DEVELOPMENT OF EXPERIMENTAL STRATEGIES FOR THE PROPHYLAXIS AND TREATMENT OF TUBERCULOSIS: Acosta A et al. [HTML]
C 029: NEW PROMISING CANDIDATES FOR DIABETES TYPE 2 TREATMENTS OBTAINED FROM NATURAL SOURCES: INHIBITORY EFFECTS ON PTP1B, DPPIV AND GLUCOSE UPTAKE IN VITRO ASSAYS: Marrero Faz E et al. [HTML]
C 030: DIFFERENTIAL REGULATION BY P1 AND P2 PURINOCEPTORS OF ATRIAL CONTRACTION IN NORMOTENSIVE AND SPONTANEOUSLY HYPERTENSIVE RATS: Jurkiewicz A et al. [HTML]
C 031: INHIBITION OF CYTOCHROME P450 BY NATURAL PRODUCTS AS AN ANTIMUTAGENESIS MECHANISM: Espinosa-Aguirre JJ. [HTML]
C 032: CHEMO-IMMUNOTHERAPY FOR CANCER: A RATIONAL SCIENTIFIC AND THERAPEUTIC: Soriano García JL. [HTML]
C 033: IMMUNOTHERAPY FOR NON HODGKIN’S LYMPHOMAS. ADVANCES IN THE USE OF MONOCLONAL ANTIBODIES: Gracia Medina E. [HTML]
C 034: EPIDERMAL GROWTH FACTOR AND GROWTH HORMONE-RELEASING PEPTIDE-6: COM-BINED THERAPEUTIC APPROACH FOR NEURODEGENERATIVE DISEASES: García del Barco D et al. [HTML]
C 035: EXPERIMENTAL HYPOTHYROIDISM DURING LACTATION ALTERS NEUROENERGETIC IN RAT CEREBELLUM: de Assis AM et al. [HTML]
C 036: IMPACT OF RARE DISEASES IN THE HEALTH POLICIES IN COUNTRIES UNDER DEVELOPMENT. EXPERIENCES AT LATIN-AMERICA AND CARIBBEAN (LA&C): Llera VA. [HTML]
C 037: ORPHAN DRUGS: DEFINITIONS, RESEARCH & DEVELOPMENT, MASTER PLANS, ACCESIBILITY AND BIOETHICAL ASPECTS: Roldán E. [HTML]
C 038: ECONOMIC EVALUATION AND ORPHAN DRUGS: Gálvez González AM. [HTML]
C 039: INTERNATIONAL COOPERATION AND ACTIONS FOR ORPHAN DRUGS. INCLUDING LATIN- AMERICA AND CARIBBEAN WITHIN THE INTERNATIONAL LANDSCAPE: Llera VA. [HTML]
C 040: USE OF GENETICALLY MODIFIED MOUSE MODELS TO STUDY MECHANISMS OF CHEMICALLY-INDUCED LIVER CANCER RISK: Grant DM. [HTML]
C 041: THE USE OF ENZYMES FOR POLYMER CONJUGATION: Pasut G. [HTML]
C 042: SIMULATION OF PLASMID RECOVERY PROCESS FOR A DNA VACCINE: Limonta M et al. [HTML]
C 043: CONTROVERSIAL POINTS ABOUT VA-MENGOC-BC®: Ochoa Azze R. [HTML]
C 044: NOVEL MODEL FOR “CALCIUM PARADOX” IN SYMPATHETIC TRANSMISSION OF SMOOTH MUSCLES: ROLE OF CYCLIC AMP PATHWAY: Bergantin LB et al. [HTML]
C 045: SELECTIVE CYTOTOXIC ACTIVITY OF 1-O-UNDECYL GLYCEROL: Hernández-Colina M et al. [HTML]
C 046: METABOLIC SYNDROME AND PLANT DRUGS: Alonso J. [HTML]
C 047: CHRONOPHARMACOLOGY: Valdés Y. [HTML]
C 048: THE ROLE OF ACTIGRAPHY IN THE STUDY OF THE SLEEP-WAKE CYCLE: Meira e Cruz M. [HTML]
C 049: PERMANENT PHARMACOLOGY UPDATING, INHERENT COMPETENCE TO PHARMA-CEUTICAL CARE: Sedeño C. [HTML]
C 050: IMPLEMENTATION OF VIRTUAL SIMULATION SOFTWARE Microlab® AND RAT CARDIO-VASCULAR IN PHARMACOLOGY 2012, MEDICAL SCHOOL OF UNMSM: Placencia M et al. [HTML]
Top page
Oral Communications
Workshop on Immunopharmacology and Biotechnology. Session; Immunopharmacology
CO 001: TOWARDS CLINICAL TRANSLATION OF T-CELL RECEPTOR GENE EDITING TO MEDIATE ADOPTIVE ANTI-TUMOR IMMUNOTHERAPY: Ciceri F et al. [HTML]
CO 002: HUMAN ANTIBODIES REACTIVE TO NEUGCGM3 GANGLIOSIDE HAVE CYTOTOXIC ANTITUMOR PROPERTIES: Rodríguez-Zhurbenko N et al. [HTML]
CO 003: PHARMACOLOGIC INTERVENTION OF CASEIN KINASE 2 (CK2)-MEDIATED PRO-SURVIVAL AND PROLIFERATIVE SIGNALING ON T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (TALL): Perera Y et al. [HTML]
CO 004: In Silico DESIGN AND FUNCTIONAL CHARACTERIZATION OF A TGFβ1 MUTEIN, ANTAGONISTIC OF TGFβ SIGNALING, WITH ANTITUMOR AND IMMUNEMODULATORS PROPERTIES: Corría Osorio J et al. [HTML]
CO 005: MOLECULAR MECHANISMS INVOLVED IN THE INHIBITION OF TUMOR CELLS PROLIFERATION EXPOSED TO ELEVATED CONCENTRATIONS OF EPIDERMAL GROWTH FACTOR (EGF): Camacho H et al. [HTML]
CO 006: CONCENTRATION OF MMP-3 AND IL-6 IN PATIENTS WITH SEPSIS AND MULTIORGAN FAILURE: Ricarte Bratti JP et al. [HTML]
CO 008: IMMUNOTRANS-ARTERIAL CHEMOEMBOLIZATION (ITACE) IN HEPATOCELLULAR CARCINOMA PATIENTS TREATED WITH ANTI-EGFR MAB NIMOTUZUMAB PLUS ADRIAMYCIN. PHASE I CLINICAL TRIAL, FINAL RESULTS: Ramos-Suzarte M et al. [HTML]
CO 009: A NOVEL PEPTIDE SELECTED FROM AN ALA-SCANNING REGULATES THE ONCOGENIC ACTIVITY OF NFKB IN CANCER CELLS: Oliva B et al. [HTML]
CO 010: NEOPLASTIC TRANSFORMATION OF HUMAN MESENCHYMAL STEM CELLS CONCERTS IMMUNE-EVASION AND PRO-INFLAMMATORY PROGRAMS IN THE ABSENCE OF IMMUNE-EDITION MEDIATED PREASSURE: Miranda-Rodríguez A et al. [HTML]
CO 011: PRECLINICAL EVIDENCES OF P3 MAB IMMUNORESTORATION CAPACITY ON SUPPRESSED BALB/c MICE: Martínez D et al. [HTML]
CO 012: PANUSIN, A NEW DEFENSIN-LIKE ANTIMICROBIAL PEPTIDE FROM THE HEMOCYTES OF SPINY LOBSTER Panulirus argus: Pacios-Michelena A et al. [HTML]
CO 013: BIOMODULINA T: IMMUNOMODULATOR NATURAL PRODUCT OF THE LIFE´S QUALITY: Aznar García E et al. [HTML]
Top page
Symposium on Clinical Trial
CO 015: ETHICAL CONSIDERATIONS IN DEVELOPING COUNTRIES IN HIV VACCINE TRIALS: Ellis G. [HTML]
CO 016: CANCER CLINICAL TRIALS: STATE OF THE ART AND THE CUBAN EXPERIENCE: Crombet-Ramos T. [HTML]
CO 017: PHARMACODYNAMICS AND PHARMACOKINETICS OF TWO FORMULATIONS CONTAINING SYNERGISTIC PROPORTIONS OF INTERFERONS ALPHA-2B AND GAMMA IN HEALTHY MALE VOLUNTEERS (SOFIA STUDY): García I et al. [HTML]
CO 019: SERUM LEVELS OF INFLAMMATORY MARKERS IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION DURING A 6 MONTH FOLLOW UP: Brizuela NY et al. [HTML]
CO 020: SUBJECT: NATIONAL BIOETHICS NETWORK AND RESEARCH IN PERU – RENABIP: Socualaya P et al. [HTML]
CO 021: CLINICAL TRIAL DESIGNS THAT CAN SPEED UP NEW DRUG DEVELOPMENT: López-Saura PA et al. [HTML]
CO 022: EFFICACY AND SAFETY OF RECOMBINANT STREPTOKINASE VERSUS HYDROCORTISONE ACETATE-BASED SUPPOSITORIES IN THE TREATMENT OF HEMORRHOIDAL DISEASE. RANDOMIZED, CONTROLLED TRIAL (THERESA-4 Study): Hernández-Bernal F et al. [HTML]
CO 023: TRIMETAZIDINE INHIBITS THE RENAL FIBROSIS INDUCED BY CYCLOSPORIN A: De la Cruz Rodríguez L et al. [HTML]
Top page
Workshop on 3Rs Alternatives in Pharmacology, Toxicology and Teaching
CO 024: ALTERNATIVE METHODS IN THE SAFETY EVALUATION OF COSMETIC: EUROPEAN SITUATION: Vinardell MP. [HTML]
CO 025: PRINCIPLE OF REDUCTION AND THE VALIDITY AND EFFICIENCY OF ANIMAL ASSAYS: Rosenkranz A. [HTML]
CO 026: ALTERNATIVE METHODS AND THE SAFETY ASSESSMENT OF HEALTH PRODUCTS: EXPERIENCE OF NATIONAL INSTITUTE OF QUALITY CONTROL IN HEALTH, BRAZIL: Fernandes Delgado I et al. [HTML]
CO 027: PROPOSED METHODS AND ESPECIALLY STEM CELLS AS POTENTIAL REPLACEMENT METHODS TO STUDY HUMAN PATHOLOGIES: Bercovier H. [HTML]
CO 028: BASIC ASPECTS OF THE TOXICOLOGICAL EVALUATION OF NANOMATERIALS: Vinardell MP et al. [HTML]
CO 029: BEST PRACTICE AND ALTERNATIVES TO ANIMAL EXPERIMENTS IN EDUCATION: Jukes N. [HTML]
CO 031: ALTERNATIVES TO THE USE OF ANIMALS IN VETERINARY MEDICINE EDUCATION: Torres M et al. [HTML]
CO 032: SUPER-SELECTIVE OPHTHALMIC ARTERY CATHETERIZATION IN THE PIG AS A TRAINING MODEL WITH POSSIBLE IMPLICATIONS FOR RETINOBLASTOMA TREATMENT: Asprea M et al. [HTML]
CO 033: USING VIDEOS AND PLASTINATED MURINE MODELS FOR TRAINING: Streber ML et al. [HTML]
CO 034: DISSECTION OF THE VENTRAL NERVE CORD-DEEP ABDONIMAL FLEXOR MUSCLE SYSTEM OF THE FRESHWATER LOBSTER OF THE Cherax GENUS: AN IN SITU MODEL FOR TEACHING PHARMACOLOGY: Islas V et al. [HTML]
Top page
Workshop on Pharmacoepidemiology
CO 036: DRUG USE IN PREGNANT WOMEN: Viroga S et al. [HTML]
CO 037: MEDICAL PRACTICE CONFIRMS CLINICAL TRIAL RESULTS OF THE USE OF INTRALESIONAL HUMAN RECOMBINANT EPIDERMAL GROWTH FACTOR IN ADVANCED DIABETIC FOOT ULCERS: López-Saura PA et al. [HTML]
CO 038: FREQUENCY OF USE OF THE MONOCLONAL ANTIBODY RITUXIMAB ON THE NATIONAL CANCER INSTITUTE OF MEXICO: ONE YEAR EXPERIENCE: López-Gamboa M et al. [HTML]
CO 039: RATIONAL USE OF MEDICINES IN PRIMARY HEALTH CARE: POLYPHARMACY IN PEOPLE AGED 60 YEARS AND OLDER: Ponce LN et al. [HTML]
CO 040: EDUCATIVE INTERVENTION ON ESSENTIAL MEDICATIONS TO BE USED IN DISASTERS BY FAMILY DOCTORS IN ARROYO NARANJO MUNICIPALITY, IN 2012: López Aguilera AF et al. [HTML]
CO 041: EFFECTIVENESS OF ANTIRETROVIRAL TREATMENT IN COLOMBIA: Machado-Alba JE et al. [HTML]
CO 042: IMPACT OF AN ANTIBIOTIC POLICY ON ANTIMICROBIAL CONSUMPTION AT COMANDANTE MANUEL FAJARDO UNIVERSITY HOSPITAL, 2011: Morejón M et al. [HTML]
CO 043: CLINICAL PHARMACIST PERFORMANCE IN MULTIPROFESSIONAL TEAM IN A TEACHING HOSPITAL: Amaral Pedroso L et al. [HTML]
CO 044: LIPID-LOWERING THERAPY EFFECTIVENESS IN A SAMPLE OF COLOMBIAN PATIENTS: Machado-Alba JE et al. [HTML]
CO 045: NSAID AND GASTROPROTECTIVE AGENTS PRESCRIPTION AT THE CLINICAL HOSPITAL “DR. MANUEL QUINTELA”: Cuñetti L et al. [HTML]
Top page
Symposium on Pharmacology of Pain
CO 046: MANGIFERIN FOR THE MANAGEMENT OF PAIN: ADVANTAGES OF ITS TRANSCIENT AND LONG TERM NEUROMODULATORY EFFECTS: Garrido BB et al. [HTML]
CO 047: ANTINOCICEPTIVE ACTIVITY OF MANGIFERIN IN FORMALIN PAIN: Espinoza de los Monteros-Zuñiga A et al. [HTML]
CO 048: ANTI-HYPERALGESIC EFFECT OF A NEUROPROTECTIVE COMPOUND IN ANIMAL MODELS OF PAIN: Castro M et al. [HTML]
CO 051: OPIOIDS UPDATE IN 2013. PAIN FREE HOSPITALS, IMPORTANCE OF ITS DEVELOPMENT IN CUBA: Yera-Nadal JL. [HTML]
Top page
Workshop of Nanopharmacology
CO 052: CRITICAL POINTS TO CONSIDER WHEN DEVELOPING PHARMACEUTICAL PRODUCTS BASED ON MICROSPHERES CONTAINING PROTEINS: Saez V. [HTML]
CO 053: SYNTHESIS, CHARACTERIZATION AND DRUG DELIVERY PROFILE OF MAGNETIC PLGA-PEG-PLGA/MAGHEMITE NANOCOMPOSITE: Pereira ED et al. [HTML]
CO 054: AFFINITY MATURATION AND FINE FUNCTIONAL MAPPING OF AN ANTIBODY FRAGMENT AGAINST A NOVEL NEUTRALIZING EPITOPE ON HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR: Lamdan H et al. [HTML]
CO 055: NANOEMULSION PREPARATIONS FROM A PLANT LIPID EXTRACT WITH WIDE RANGE OF APPLICATIONS IN MEDICINE: Turiño L et al. [HTML]
CO 056: DEVELOPMENT AND CHARACTERIZATION OF MANGIFERIN NANOCAPSULES: Moura UJ et al. [HTML]
CO 057: COMBINATION EFFECT OF SONOPHORESIS AND IONTOPHORESIS ON ANTIPYRINE TRANSDERMAL PENETRATION: Aoyagi T et al. [HTML]
CO 058: NANOPARTICLES AS DRUG CARRIERS: CHARACTERISTICS AND PERSPECTIVES: Oropesa-Nuñez R et al. [HTML]
CO 059: NOVEL PEGYLATION TECHNOLOGIES FOR THE DEVELOPMENT OF NEXT GENERATION BIODRUGS: Ikeda Y et al. [HTML]
CO 060: PEGYLATION: AN EFFECTIVE TOOL FOR BIOMASKING: Ramón JA et al. [HTML]
CO 061: NANOSTRUCTURE: SURFACE MODIFICATIONS BY LASER BEAM: Guastaldi AC. [HTML]
Top page
 Session for the Constitution of the Latin-American – Iberoamerican Network for 3 Rs Alternatives
CO 062: THE ROLE OF THE BRAZILIAN CENTER FOR VALIDATION OF ALTERNATIVE METHODS (BraCVAM) IN THE PROCESS OF VALIDATION IN BRAZIL: LOOKING TO THE FUTURE: Presgrave O et al. [HTML]
CO 063: ALTERNATIVE METHODS AT THE END OF THE WORLD: Asprea M. [HTML]
CO 064: CUBAN EXPERIENCE IN THE DEVELOPMENT OF 3RS IN THE FIELD OF TOXICOLOGY AND METABOLISM OF DRUGS: Rodeiro I. [HTML]
CO 065: WHY AND FOR WHAT CREATING A LATINAMERICAN-IBEROAMERICAN NETWORK FOR ALTERNATIVES?: Chovel ML. [HTML]
Top page
Workshop on Immunopharmacology and Biotechnology. Session; Immunopharmacology
CO 066: CIGB-814, A PEPTIDE AS IMMUNOMODULATOR FOR THE TREATMENT OF RHEUMATOID ARTHRITIS: Domínguez MC et al. [HTML]
CO 067: ENHANCEMENT OF THE INHIBITORY EFFECT OF AN IL-15 ANTAGONIST PEPTIDE BY ALANINE SCANNING: Rodríguez Y et al. [HTML]
CO 068: THE LONG PENTRAXIN PTX3: A NON-REDUNDANT COMPONENT OF THE HUMORAL INNATE IMMUNITY AND A PROMISING BIOMARKER IN INFLAMMATORY CONDITIONS: Garlanda C et al. [HTML]
CO 069: LEVELS OF SOLUBLE IL-15, IL-6, TNFΑ AND IL-15RΑ IN SYNOVIAL FLUID AND MEMBRANE BOUND IL-15 ON SYNOVIAL CELLS FROM PATIENTS WITH RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS: Machado-Díaz AC et al. [HTML]
CO 070: IMMUNOMODULATING AND ENHANCING ACTIVITIES OF SOLUBLE GLUCANS FROM Sacharomyces cerevisiae ASSESED BY MONOCYTE ACTIVATION TEST: Pardo-Ruiz Z et al. [HTML]
CO 071: EARLY PHASE OF SYSTEMIC REACTION TO ORAL ASPIRIN CHALLENGE IS RELATED TO AN INCREASE IN THE LEVELS OF IL-6 AND THE PERCENTAGE OF EFFECTORS MEMORY TCELLS: Pérez-Novo CA et al. [HTML]
Top page